Genmab — September 2017
-
Og her tænker jeg på Jan's ordvalg for nylig. Her kiggede han fremad - meget rigtigt og fornuftigt - og her betegnede han Genmab som en kursraket. Husker ikke om han havde en tidsplan på den, men jeg er sikker på at mange forventer det sker indenfor "en overskuelig fremtid".
-
-
-
Verastem (NASDAQ:VSTM) is up 30% premarket on average volume in response to its announcement of positive results from a Phase 3 clinical trial, DUO, assessing duvelisib compared to ofatumumab (Novartis' ARZERRA) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
-
Darzalex for lung cancer https://m.indiamart.com/proddetail.php?i=14901049948 ???
-
Duvelisib, the Verastem drug, is a PI3K kinase inhibitor https://en.wikipedia.org/wiki/Duvelisib that works in a different way than the CD20 antibody ofatumumab. Novartis likely bought the Arzerra rights due to the potential in MS and not so much in CLL and other cancers where Ibrutinib and other kinase inhibitors see much
success -
Godmorgen. Partial clinical hold på opdivo studier i mm. Går mest ud over elotuzomab, men også dara fase 1 pauseres. Dog fortsætter pt med klinisk respons. https://investors.bms.com/iframes/press-releases/press-release-details/2017/Bristol-Myers-Squibb-Provides-an-Update-on-Three-Opdivo-based-Combination-Clinical-Studies-in-Multiple-Myeloma-/default.aspx
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind